LXRX - Lexicon Pharmaceuticals up 9i% on mid-stage study for diabetic neuropathy drug

• Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is up 9% in after-hours trading after releasing phase 2 top-line data for LX9211, its candidate for diabetic neuropathy.
• The drug met its primary endpoint, statistically significant reduction in average daily pain score at week 6 compared to placebo in the low dose arm. Separation from placebo was seen by week 1 in both dose arms.
• LX9211 is AAK1 inhibitor that has received U.S. FDA Fast Track designation.
• The candidate is also in another phase 2 proof-of-concept study in post-herpetic neuralgia. The company anticipates top-line results at the end of Q3.
• Seeking Alpha contributor Avisol Capital Partner, which rates Lexicon ( LXRX ) a buy, sees the stock as a high risk-reward situation .

For further details see: